While most pharma exporters rely on unbranded generic sales with lower margins, Balaxi earns almost all its revenues from its own branded generics. This leads to better customer stickiness, brand loyalty, and higher gross margins. Due to its in-house distribution model and direct sales network, Balaxi has a working capital cycle of just 30–45 days in many countries. This is significantly lower than industry standards, where credit cycles often stretch beyond 90–120 days. Balaxi has an aggressive product pipeline, targeting 200+ new registrations every year. This gives it a deep and diversified portfolio across therapeutic areas like anti-infectives, anti-malarials, cardiovascular, and dermatology.